news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

The two A-share companies were investigated on the same day, respectively involving illegal and irregular information disclosure and short-term trading of company stocks.

Fudan Fuhua (600624) announced on the evening of August 5 that the company received a "Notice of Case Filing" from the China Securities Regulatory Commission on August 5. The China Securities Regulatory Commission decided to file a case against the company because the company was suspected of violating laws and regulations in information disclosure.

Fudan Fuhua said that currently, the company's production and operation are normal. During the investigation, the company will actively cooperate with the China Securities Regulatory Commission's investigation and strictly comply with the relevant laws and regulations and regulatory requirements to fulfill its information disclosure obligations in a timely manner.

Fudan Fuhua's predecessor was Fudan University Technology Development Company, which was founded in 1984. The company was restructured in June 1992 and listed on the Shanghai Stock Exchange in January 1993, becoming the first listed company among universities in China.

In September 2020, in accordance with the spirit of the central government's reform of the enterprise system of higher education institutions, Fudan University transferred all of its shares in the company to Shanghai Fengxian Investment (Group) Co., Ltd. free of charge, and the company's controlling shareholder was changed to Shanghai Fengxian Investment (Group) Co., Ltd.

As a company that has been deeply involved in the biopharmaceutical field for many years, Fudan Fuhua's main business covers multiple links such as drug research and development, production and sales. In recent years, the company has gradually established a competitive position in the industry through continuous technological innovation and market expansion.

Since July, the abnormal fluctuation of Fudan Fuhua's stock price has attracted market attention. The market shows that in the seven trading days from July 17 to July 25, the company's stock price achieved a growth of more than 52%, and it was listed on the Dragon and Tiger List six times in the past month.

Fudan Fuhua announced on the evening of July 25 that the company's stock rose by more than 30% on July 23, July 24, and July 25, 2024, and the stock price fluctuated greatly in the short term. After the company's self-examination, except for the matters disclosed by the company, as of the date of disclosure of this announcement, there have been no other major changes in the company's daily production and operation and external environment.

Fudan Fuhua also gave a performance forecast for July 10: According to preliminary estimates by the financial department, the net profit attributable to shareholders of the listed company in the first half of 2024 is expected to be between -22.5 million yuan and -15 million yuan, which will result in a loss. "The company asks investors to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently," the announcement said.

Huiyu Pharmaceuticals was also investigated on the same day. On the evening of August 5, Huiyu Pharmaceuticals (688553) announced that Ding Zhao, chairman and general manager of the company, received the "Notice of Filing of a Case by the China Securities Regulatory Commission" on August 5, 2024. He was suspected of short-term trading of Huiyu Pharmaceuticals stocks. According to relevant laws and regulations, it was decided to file a case against him.

Huiyu Pharmaceutical stated that this matter is an investigation into Ding Zhao personally and will not have a significant impact on the operation of the board of directors and daily business activities. Ding Zhao will actively cooperate with the investigation of the China Securities Regulatory Commission.

Huiyu Pharmaceutical is a research and development-driven comprehensive pharmaceutical company that mainly engages in the research and development, production and sales of anti-tumor and injectable drugs. It was listed on the Science and Technology Innovation Board in October 2021.

On April 29, Huiyu Pharmaceutical disclosed the details of this short-term transaction. From August 23, 2023 to September 27, 2023, Ding Zhao's mother Yan Zhao bought a total of 1,239 shares of the company's stock (2 transactions), with a total transaction amount of 17,500 yuan; sold a total of 14,430 shares of the company's stock (7 transactions), with a total transaction amount of 209,500 yuan, and a total transaction income of 192,100 yuan.

Huiyu Pharmaceuticals said that the company attached great importance to the incident after learning about it and promptly checked the relevant situation. Ding Zhao and his relatives deeply apologized for the above-mentioned violations and actively cooperated with the investigation. After verification, Ding Zhao was unaware of his mother Yan Zhao's buying and selling of the company's stocks, and Yan Zhao did not consult Ding Zhao on the matter of buying and selling the company's stocks. There was no situation of trading the company's stocks after learning insider information and using insider information to seek benefits, and there was no subjective intention to violate the regulations. At the same time, Yan Zhao has handed over all the profits of 192,100 yuan from this short-term transaction to the company.

Editor: Chen Lixiang

Proofreader: Yang Lilin